EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis
The recommendations advise on managing cardiovascular health in patients with gout, vasculitis, systemic sclerosis, myositis, Sj ögren syndrome, lupus, antiphospholipid syndrome, and other diseases.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 24, 2022 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Scientists pinpoint mechanisms associated with severe COVID-19 blood clotting
Researchers found circulating antiphospholipid antibodies, which can be more common among people with autoimmune disorders. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 17, 2022 Category: American Health Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
COVID-19 vaccination: blood clotting information for healthcare professionals, PHE ( updated 23rd August 2021)
Information for healthcare professionals on blood clotting following COVID-19 vaccination.
23 August 2021Updated guidance document.
8 June 2021Updated to include: antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 23, 2021 Category: Consumer Health News Source Type: news
A 28-Year-Old With Antiphospholipid Syndrome A 28-Year-Old With Antiphospholipid Syndrome
This week ' s question involves antiphospholipid syndrome.Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2021 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
COVID-19 vaccination: blood clotting information for healthcare professionals, PHE (updated 8th June 2021)
This guidance has been updated to include antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data. 8 June 2021Updated to include: antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data. 7 May 2021Updated information for healthcare professionals on blood clotting following COVID-19 vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 9, 2021 Category: Consumer Health News Source Type: news
COVID-19 vaccination: blood clotting information for healthcare professionals, PHE (updated 8th June 2021)
Information for healthcare professionals on blood clotting following COVID-19 vaccination.
8 June 2021Updated to include: antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data.
7 May 2021Updated information for healthcare professionals on blood clotting following COVID-19 vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 8, 2021 Category: Consumer Health News Source Type: news
Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
JOHN STAPLETON on the 'cure' that killed his wife Lynn Faulds Wood
JOHN STAPLETON: Lynn Faults Wood suffered a stroke caused by a disease of which few people have heard. A disease with the hard-to-remember name of antiphospholipid syndrome (Source: the Mail online | Health)
Source: the Mail online | Health - April 20, 2021 Category: Consumer Health News Source Type: news
Managing Diffuse Peripheral Ischemia in Antiphospholipid Syndrome Managing Diffuse Peripheral Ischemia in Antiphospholipid Syndrome
A complex case of refractory peripheral ischemia in a 39-year-old man with APS and type 1 diabetes.HSS Grand Rounds Complex Cases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2021 Category: Consumer Health News Tags: Rheumatology Clinical Case Source Type: news
Lipid presentation by the protein C receptor links coagulation with autoimmunity
Antiphospholipid antibodies (aPLs) cause severe autoimmune disease characterized by vascular pathologies and pregnancy complications. Here, we identify endosomal lysobisphosphatidic acid (LBPA) presented by the CD1d-like endothelial protein C receptor (EPCR) as a pathogenic cell surface antigen recognized by aPLs for induction of thrombosis and endosomal inflammatory signaling. The engagement of aPLs with EPCR-LBPA expressed on innate immune cells sustains interferon- and toll-like receptor 7–dependent B1a cell expansion and autoantibody production. Specific pharmacological interruption of EPCR-LBPA signaling attenua...
Source: ScienceNOW - March 11, 2021 Category: Science Authors: Müller-Calleja, N., Hollerbach, A., Royce, J., Ritter, S., Pedrosa, D., Madhusudhan, T., Teifel, S., Meineck, M., Häuser, F., Canisius, A., Nguyen, T. S., Braun, J., Bruns, K., Etzold, A., Zechner, U., Strand, S., Radsak, M., Strand, D., G Tags: Immunology, Medicine, Diseases, Online Only r-articles Source Type: news
